Which bills lived or died after the Iowa Legislature's second "funnel" deadline on Friday? Check out the complete list.
6d
Raw Story on MSN'Worst fears coming true': Conservative WSJ hits Trump for letting Cabinet member run amokHealth advocates sounded the alarm when President Donald Trump first nominated Robert F. Kennedy Jr. to lead the Department ...
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven ...
Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple ...
MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics today announced the appointment of Susan Pandya, M.D., as an ...
2d
What to Expect on MSNWhat a Dietitian Wants You to Know About Organic Baby FormulaW ith numerous brands of baby formula on the market, choosing the right one can be quite challenging. On top of that, there ...
Dr. Marks was asked to leave and then subsequently wrote that he did not want to become “subservient to [Secretary Kennedy’s] misinformation and lies.” Peter Marks is not a hero of the resistance but ...
Passersby Hunnewell Elementary School on April 1 will notice the sign out front with the school name on it has been replaced ...
The Food and Drug Administration’s chief tobacco regulator has been forced out. Brian King's departure Tuesday comes just ...
As a longtime dog owner, I assumed that each bag of my dogs’ commercial pet food was closely monitored by the federal Food and Drug Administration (FDA ... brands employ a board-certified ...
FDA signage outside the White Oak Campus. Credit: Tada Images/Shutterstock. A leading food and health advisory agency has described the mass layoffs at the US Food and Drug Administration (FDA) as ...
According to the FDA, reproxalap did not demonstrate efficacy in treating ocular symptoms of dry eye disease. Aldeyra plans to resubmit the new drug application with new trial data later this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results